Improving Long-Term Outcomes in Chronic Heart Failure Webcast
Release Date: October 14, 2015
Expiration Date: October 14, 2016
Estimated time to completion: 0.75 hours
Paul J. Hauptman, MD
Department of Medicine
Saint Louis University
School of Medicine
Saint Louis, Missouri
Heart failure (HF) is a complex clinical syndrome that is associated with increased morbidity, poor health-related quality of life, and mortality. The goals of HF treatment are to improve symptoms, slow disease progression, and prolong survival. Since the diagnosis of HF relies heavily on clinical judgment, the diagnosis of chronic HF is often missed and delayed. Additionally, despite the availability of guidelines for the treatment and management of patients with chronic HF, adherence to these guidelines remains poor. Given the various comorbidities and contraindications in patients with chronic HF, treatment and management continues to challenge physicians. This is reflected in the fact that HF is currently the leading cause of morbidity, hospitalization, and death worldwide.
This educational program will provide a case- and clinical guideline-based review of best practices for the management of patients with HF.
This educational initiative has been designed for internal medicine and family physicians involved in the management of patients with chronic HF.
Upon completion of this educational activity, participants should be able to:
- Recognize and classify HF in patients according to disease stage and class
- Review current guidelines for the pharmacologic treatment and management of patients with chronic HF
- Assess clinical evidence on existing and emerging treatments in chronic HF to provide personalized therapy toward decreasing hospitalizations and mortality
- Identify non-physiologic considerations in HF management and outcomes
Directions to Learner
There are no fees for participating and receiving CME credit for this activity. During the period October 14, 2015 through October 14, 2016, participants must:
- Read the learning objectives and faculty disclosures
- Complete the pretest
- Study the educational activity
- Complete the posttest by recording the best answer to each question in the answer key on the evaluation form
- Complete the evaluation form
A statement of credit will be issued upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better. Your statement of credit will be sent to you within 4 weeks.
Accreditation Council for Continuing Medical Education Accreditation Statement
Integrity Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Integrity Continuing Education designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest (COI)
Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent COI they may have as related to the content of this activity. All identified COI are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The following faculty/planners reported their financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Paul J. Hauptman, MD
Consultant: Amgen, BioControl Medical, CardioMEMs, Novartis, Otsuka Pharmaceuticals, Relypsa
Investigator: Alnylam, Celladon, NHLBI
Speaker: Amgen, Otsuka Pharmaceuticals, Zoll
Patima Tanapat, PhD, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Novartis do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Integrity Continuing Education, Inc. and Novartis. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
When you participate in an online educational activity sponsored by Integrity CE, you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and...(continued)
Minimum System Requirements
Windows XP, Windows 2000, Windows Vista, and Windows 7
Intel Pentium 4, 2.33 + GHz (or equivalent)
Adobe® Flash® Player 10
For optimal performance, the use of Internet Explorer is not recommended.
Mac OS X v10.4 or later
1.8GHz or faster (or equivalent)
Intel Core Duo 1.33GHz or faster (or equivalent)
Adobe® Flash® Player 10
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.
|Sponsored by Integrity Continuing Education, Inc.|
|Supported by an educational grant from Novartis.|